Sutent Approved for Rare Pancreatic Cancer (HealthDay)
HealthDay – MONDAY, May 23 (HealthDay News) — U. S. Food and Drug Administration approval of Sutent (sunitinib) has been expanded to include people with neuroendocrine pancreatic cancer that is inoperable or has metastasized to other parts of the body.
View full post on Yahoo! News: Health News
Leave a Reply